Melasma & Pigmentation Treatment in Thiruvananthapuram – Expert Solutions | DermaVue

Name: Melasma Treatment in Thiruvananthapuram
Brand: DermaVue
SKU: SVC-TVM-MELASMA
Price: 300 INR
Availability: InStock
Rating: 4.7 (1309 reviews)

DermaVue Medical Team

MD DVL DERMATOLOGY · DERMAVUE THIRUVANANTHAPURAM (TRIVANDRUM)

Melasma Treatment in Thiruvananthapuram

4.7 (1309+ Reviews) US-FDA Approved Lasers Fitzpatrick IV-V Specialists UV Index 11-12 Protocols

Melasma responds to a staged clinical protocol, not a single cream. At DermaVue Thiruvananthapuram (Trivandrum), MD DVL dermatologists begin with Wood lamp typing to classify melasma as epidermal, dermal, or mixed — a step that determines whether topical agents alone will suffice or whether oral tranexamic acid and low-fluence Q-switched Nd:YAG 1064 nm laser toning are added. Protocols are calibrated for Fitzpatrick IV–V skin and the sustained UV index of 11–12 recorded year-round in coastal Kerala. 1309+ verified Google reviews across the network. Consultation ₹300.

WhatsApp DermaVue Thiruvananthapuram

4.7★ — 1309+ Reviews US-FDA Approved Lasers IADVL Registered Board-Certified Dermatologists Physician-Led Treatment

SERVING ALL OF THIRUVANANTHAPURAM

DermaVue's Poojapura clinic is 12 minutes from Pattom Junction, 25 minutes from Kowdiar Palace, and 30 minutes from Technopark Phase-1 via NH-66.

Pattom 12 min Kowdiar 14 min Vellayambalam 16 min Nalanchira 10 min Kesavadasapuram 16 min Ulloor 15 min Technopark 18 min Kazhakkoottam 22 min Sreekaryam 20 min Medical College 8 min Peroorkada 18 min Mannanthala 25 min Kovalam 30 min Balaramapuram 25 min Pappanamcode 22 min Venganoor 25 min Kalliyoor 18 min Menamkulam 20 min Neyyattinkara 35 min Nedumangad 38 min Attingal 40 min Varkala 45 min Vakkom 35 min Kattakada 30 min Nagercoil 65 min

ENVIRONMENTAL INTELLIGENCE

The Environmental Case for a Tropical-Specific Protocol

Thiruvananthapuram sits at 8.5°N, where the solar zenith is near-vertical for most of the calendar year. The Indian Journal of Dermatology, Venereology and Leprology (IJDVL) reports melasma prevalence of 20–30% among adult Indian women in dermatology outpatient cohorts, with tropical coastal latitudes and Fitzpatrick IV–V phototype driving the upper end. Three environmental variables compound the genetic and hormonal susceptibility most patients already carry.

☼

UVA Exposure With No True Off-Season

Melasma is driven predominantly by UVA (320–400 nm) and visible light — both of which penetrate cloud cover and glass. Published UV monitoring for Kerala's coast shows the midday UV index crossing 11 on roughly 80% of days across the calendar year, and the Kovalam–Shanghumugham stretch adds measurable reflectance off sand and water. This sustained UVA load keeps melanocytes in a chronically upregulated state, which is why topical lightening agents fail without an equally rigorous photoprotection layer.

❄

Heat, Vascularity and the Dermal-Epidermal Junction

Melasma histology consistently shows increased dermal vasculature and vascular endothelial growth factor (VEGF) expression adjacent to hyperactive melanocytes. Prolonged ambient heat and repeated thermal shifts — air-conditioned interiors into 80–85% humidity and back — drive low-grade vasodilation at precisely this dermal-epidermal interface. This is why chronic facial flushing, rosacea-adjacent vascular reactivity and melasma so often coexist, and why a purely pigment-focused protocol without vascular and barrier support under-performs in tropical climates.

⚠

Sunscreen Under-Use and Pharmacy Steroid Misuse

Published Indian cohort studies report regular sunscreen use among only a minority of melasma patients at presentation, and a recognised proportion arrive having already self-treated with over-the-counter triple-combination creams containing potent topical steroids such as clobetasol. Steroid-driven initial lightening is followed by rebound hyperpigmentation, telangiectasia and — with prolonged use — exogenous ochronosis. Reversing this damage before starting definitive therapy is an unspoken but routine first step in South Indian dermatology practice.

Quick Melasma Facts

Meta-analysis · 22 RCTs · 1,280 patients · MASI score endpoint

Across pooled randomised controlled trials, oral tranexamic acid at 250 mg twice daily produced statistically significant reductions in Melasma Area and Severity Index (MASI) scores from eight to twelve weeks, with a favourable adverse-event profile at this dose range. The drug acts upstream of the melanogenic cascade — it inhibits plasminogen activation on keratinocytes, reducing arachidonic acid and α-melanocyte-stimulating hormone release that UV would otherwise trigger. MD DVL dermatologists at DermaVue Thiruvananthapuram screen for thromboembolic risk, combined oral contraceptive use and smoking history before initiating therapy, in line with IADVL consensus guidance.

A PROTOCOL, NOT A PRODUCT

The DermaVue Melasma Protocol — Five Staged Interventions

Melasma is a chronic, relapsing disorder of melanocyte hyperactivity with epidermal, dermal and vascular components. Effective control requires interventions at each layer, sequenced in the order the evidence supports — not a single laser or cream marketed as a cure.

1. Clinical Classification

Wood lamp examination separates epidermal melasma (accentuates under UV-A) from dermal (does not accentuate) and mixed subtypes. Dermoscopy confirms pattern; Fitzpatrick phototype and baseline MASI score are recorded. This classification predicts which modalities will respond.

→

2. Kligman-Derived Topical Therapy

Modified Kligman formula — hydroquinone, tretinoin and a mid-potency topical steroid, time-limited and tapered — remains the IADVL first-line. Non-hydroquinone alternatives (azelaic acid 20%, cysteamine 5%, thiamidol, tranexamic acid topical) are used for maintenance, sensitive skin, or patients unsuitable for hydroquinone.

→

3. Oral Tranexamic Acid

250 mg twice daily for 8–12 weeks after screening for thromboembolic risk and hormonal contraceptive use. Systematic reviews report significant MASI reduction versus placebo at this dose, with a low adverse-event signal when prescribed under dermatology supervision.

→

4. Low-Fluence Q-Switched Nd:YAG Laser Toning

1064 nm at sub-photothermolytic fluence (typically 1.6–2.0 J/cm², large spot, 5–10 passes), spaced two to four weeks apart, for mixed and recalcitrant cases. Used as an adjunct to — not a replacement for — medical therapy. MNRF and high-fluence ablative lasers are actively avoided in Fitzpatrick IV–V melasma because of PIH risk.

→

5. Tinted Iron-Oxide Photoprotection & Maintenance

Broad-spectrum SPF 50+ with iron oxides for visible-light blockade — the wavelength range that activates melasma in darker skin types — reapplied every 3–4 hours. Quarterly dermatologist review with serial MASI scoring tracks relapse. This maintenance phase is where long-term outcomes are won or lost.

Evidence base: Low-fluence Q-switched Nd:YAG 1064 nm laser toning, combined with topical therapy and strict photoprotection, has been evaluated in multiple peer-reviewed studies (IJDVL, Journal of Cosmetic and Laser Therapy, Nature Scientific Reports) showing statistically significant MASI reduction versus topical therapy alone, with the caveat that laser monotherapy is inferior to combined medical therapy and relapse is universal without maintenance. DermaVue follows this combined-therapy paradigm rather than marketing laser as a standalone solution.

OCCUPATIONAL DERMATOLOGY

Occupational and Hormonal Trigger Profiles We See Most Often

Classifying the driver is as important as classifying the depth. In our Thiruvananthapuram practice, three trigger profiles account for the majority of melasma presentations, and each shifts the protocol.

The hormonal profile — onset during pregnancy (chloasma), combined oral contraceptive use, or the peri-menopausal window — typically presents with symmetrical centrofacial or malar patches that darken rapidly in summer. Oral tranexamic acid is generally deferred during pregnancy and in patients on combined contraceptives; management centres on pregnancy-safe azelaic acid, vitamin C and rigorous photoprotection until the hormonal driver is addressed.

The chronic-UV profile — two-wheeler commuters, field roles, outdoor sales and sports coaching — presents with denser lateral cheek and mandibular pigmentation. Protocols here front-load photoprotection, add oral tranexamic acid earlier, and delay laser toning until the UV exposure pattern can be genuinely modified.

The indoor-lighting and heat-cycling profile — long shifts under fluorescent and LED lighting with repeated transitions between air-conditioning and ambient heat — presents with malar melasma accompanied by dull, dehydrated texture. Visible-light photoprotection with tinted iron-oxide sunscreen and barrier-repair ceramide moisturiser are specifically added for this group, because standard clear chemical sunscreens do not adequately block the visible-light spectrum implicated in darker-skin melasma.

KNOW THE DIFFERENCE

Why Melasma Requires a Dermatologist, Not a Salon

Melasma treatment involves prescription medications, laser calibration for specific skin types, and clinical monitoring for adverse effects. In Thiruvananthapuram, a number of beauty salons and technician-operated clinics advertise "pigmentation removal" using chemical peels or uncalibrated laser devices. The risk is real.

Safe Medical Brightening (DermaVue)

Regulates melanin production at the cellular level through tyrosinase inhibition
Evidence-based agents: Tranexamic acid, arbutin, vitamin C, azelaic acid, retinoids
MD-supervised protocols with Wood lamp assessment and progress monitoring
CDSCO-compliant formulations meeting Indian drug safety standards
Gradual, sustainable results with maintained skin health and barrier function

Avoid Chemical Bleaching (Unregulated)

Destroys melanocytes causing irreversible damage and paradoxical darkening
Mercury-based formulas: Some imported creams contain up to 2,900× the safe mercury limit
Unsupervised use with no clinical assessment or safety monitoring
Imported unregulated creams bypassing CDSCO safety standards
Ochronosis risk: Permanent bluish-black discoloration from chronic misuse

Patient Safety Alert: WHO and CDSCO have flagged multiple imported "skin whitening" creams sold in Kerala markets for mercury levels exceeding 2,900 times the permissible limit. These products cause kidney damage, neurological toxicity, and permanent skin damage. Always consult a board-certified dermatologist before using any depigmenting agent. See our skin conditions guide for more information.

Effective Melasma Treatments Explained

SEASONAL PROTOCOL ADJUSTMENTS

Seasonal Melasma Management in Thiruvananthapuram

Melasma behaves differently across Thiruvananthapuram's seasons, and treatment protocols adjust accordingly.

Peak UV March – May

UV index reaches 13-15 midday. Treatment focus shifts toward maintenance and aggressive photoprotection. New laser sessions may be paused for patients with outdoor occupations during this window. Oral tranexamic acid continues.

Monsoon June – September

Cloud cover reduces but does not eliminate UV (index still 10-11 on overcast days). Humidity peaks at 85-88%. Water-resistant sunscreen formulations replace standard ones. Monsoon is actually an effective treatment window — reduced UV allows topical agents to work with less interference.

Wedding + NRI October – March

Peak demand period. Bridal clients beginning dark patches treatment should start by July for a December wedding — allowing 5-6 months for the full protocol. NRI patients visiting from the Gulf during December-January can begin a protocol at TVM and continue maintenance through DermaVue's multi-clinic network.

TRANSPARENT OUTCOMES

What the Evidence Says About Timelines and Relapse

Melasma is a chronic, relapsing disorder of melanocyte regulation. Published literature and IADVL consensus are explicit on this point: no medication, laser or peel is curative. Any clinic advertising permanent removal is either uninformed or marketing over medicine. What rigorous treatment does deliver is meaningful, measurable control — typically a reduction in MASI score that patients and observers can see in a mirror, not just in a graph.

The realistic clinical trajectory is as follows. Weeks 1–4 are an onboarding phase: barrier repair, initiation of topical therapy and photoprotection, and treatment of any prior steroid damage. Visible lightening is often minimal here. Weeks 8–12 are where combined topical plus oral tranexamic acid therapy produces the first statistically and clinically significant MASI reductions in the published trial data. Months 4–6 are where laser toning, if indicated, is layered in and epidermal components typically show the largest response. Dermal and mixed components improve more slowly and incompletely.

Relapse rates without maintenance are high — reported in the 50–80% range in follow-up studies across populations. With a maintenance phase built around quarterly dermatologist review, rotating non-hydroquinone topicals and daily tinted SPF 50+, most patients hold the gains they worked months to achieve. DermaVue's approach is to set that expectation clearly at the first visit rather than after a disappointing relapse. For adjacent pigment concerns, see our pigmentation and skin-tone treatment page in Thiruvananthapuram.

INTERACTIVE ASSESSMENT

Melasma Severity Self-Checker

Answer 4 quick questions and discover your likely pigmentation type with personalized treatment recommendations from our Thiruvananthapuram specialists.

Where is your pigmentation located?

When did the pigmentation first appear?

How would you describe the appearance?

How does sun exposure affect your pigmentation?

COMPARE YOUR OPTIONS

DermaVue vs Other Clinics for Melasma Treatment

Feature	DermaVue TVM	Technician Clinic	Beauty Salon
Who Treats You	✓ Board-Certified Dermatologist (MD DVL)	✕ Technician or Beautician	✕ Beautician
Skin Type Assessment	✓ Wood's Lamp + Fitzpatrick Classification	✕ Visual Guess	✕ None
Laser Calibration	✓ Low-Fluence Q-Switched Nd:YAG, Per Skin Type	✕ Fixed Settings, Operator-Dependent	✕ Not Applicable
Oral Medication	✓ Tranexamic Acid with Contraindication Screening	✕ Cannot Prescribe	✕ Cannot Prescribe
Adverse Outcome Management	✓ Immediate Clinical Intervention	✕ Refer to Hospital	✕ Refer to Hospital
Protocol Adjustment	✓ Every 4-6 Weeks Based on Response	✕ Repeat Same Treatment	✕ Repeat Same Treatment
US-FDA Approved Equipment	✓ Yes	✕ Variable	✕ No
Reviews	✓ 4.7★ — 1309+ Google Reviews	✕ Few / No Reviews	✕ Unverified

Understanding Pigmentation Causes

FREQUENTLY ASKED QUESTIONS

Melasma Treatment FAQs — Thiruvananthapuram

What is melasma and how is it diagnosed at DermaVue Thiruvananthapuram?

Melasma is a chronic, acquired disorder of melanocyte regulation that causes symmetrical brown or grey-brown patches, most often on the cheeks, forehead, upper lip and jawline. At DermaVue Thiruvananthapuram (Trivandrum), diagnosis is clinical and carried out by MD DVL dermatologists using a structured sequence: a history focused on hormonal, drug and sun-exposure triggers; Wood lamp examination to classify the pigment as epidermal, dermal or mixed; dermoscopy to confirm the pattern; and a baseline MASI (Melasma Area and Severity Index) score to track response objectively at follow-up.

What is the difference between epidermal, dermal and mixed melasma, and does it change treatment?

Epidermal melasma sits in the upper skin layer and accentuates under Wood lamp UV-A illumination. It responds best to topical therapy because the pigment is within reach of creams. Dermal melasma lies deeper, does not accentuate under Wood lamp, and responds poorly to topicals alone — it typically needs oral tranexamic acid and, in selected cases, low-fluence Q-switched Nd:YAG laser toning as an adjunct. Mixed melasma, the commonest subtype in South Indian skin, requires a combined protocol. Classification therefore directly determines the protocol, which is why every DermaVue consultation begins with Wood lamp examination rather than straight into laser.

What is the Kligman formula and is it still first-line for melasma?

The modified Kligman formula combines hydroquinone, tretinoin and a mid-potency topical steroid. In IADVL and global consensus guidance it remains the most evidence-supported first-line topical for moderate-to-severe melasma. At DermaVue it is prescribed as a time-limited induction (typically 8–12 weeks) and then tapered onto non-hydroquinone maintenance agents such as azelaic acid, cysteamine, thiamidol or topical tranexamic acid, to minimise the risk of exogenous ochronosis and steroid-related adverse effects.

Is hydroquinone safe, and how long can it be used?

Hydroquinone at 2–4% remains the most extensively studied topical depigmenting agent and is considered safe when prescribed under dermatology supervision for a time-limited course. Prolonged, unmonitored use — especially through over-the-counter combination creams — is associated with exogenous ochronosis (a permanent blue-grey discolouration) and paradoxical darkening. DermaVue dermatologists prescribe hydroquinone in structured induction cycles with planned tapering and regular review, and offer non-hydroquinone alternatives (cysteamine 5%, thiamidol, azelaic acid 20%) for patients who require long-term therapy.

How effective is oral tranexamic acid for melasma and is it safe?

Meta-analyses of randomised controlled trials — most notably a pooled review of 22 RCTs and 1,280 patients — report that oral tranexamic acid at 250 mg twice daily produces statistically significant reductions in MASI score versus placebo over 8–12 weeks. At this low dose the adverse-event profile is favourable and does not meaningfully increase thromboembolic risk in screened patients. It is contraindicated in people with a history of deep vein thrombosis, pulmonary embolism, stroke, active malignancy, pregnancy, and those on combined hormonal contraceptives. DermaVue dermatologists screen for these before prescribing.

Which laser is safest for melasma on Fitzpatrick IV-V Indian skin?

Low-fluence Q-switched Nd:YAG 1064 nm laser toning is the only laser modality with a reasonable safety profile in Fitzpatrick IV–V melasma, and even then it is used as an adjunct to topical and oral therapy, not as a standalone solution. High-fluence Q-switched, IPL, ablative and aggressive microneedling radiofrequency (MNRF) settings are deliberately avoided in darker skin melasma because they frequently trigger post-inflammatory hyperpigmentation — the very outcome patients are trying to reverse. Any clinic offering a single laser session as a melasma cure is ignoring the published evidence.

Why do regular sunscreens fail in melasma and what is iron-oxide tinted SPF?

Standard clear chemical sunscreens primarily block UVB and a portion of UVA. Melasma in darker skin types, however, is also driven by visible light (400–700 nm), which ordinary sunscreens do not meaningfully absorb. Tinted sunscreens containing iron oxides physically block visible light and have been shown in controlled studies to outperform non-tinted broad-spectrum sunscreens in melasma-prone skin. DermaVue therefore recommends a broad-spectrum SPF 50+ with iron oxides, reapplied every 3–4 hours, as a non-negotiable layer of the protocol.

Can melasma be treated during pregnancy (chloasma)?

Pregnancy-induced melasma is called chloasma and is driven by oestrogen, progesterone and melanocyte-stimulating hormone. Definitive therapy is generally deferred until after delivery and breastfeeding, because hydroquinone, tretinoin, oral tranexamic acid and several laser procedures are contraindicated or poorly studied in pregnancy. During pregnancy DermaVue focuses on what is safe and effective: rigorous broad-spectrum tinted photoprotection, azelaic acid 20% (pregnancy category B), vitamin C serums and gentle barrier repair. Many chloasma cases fade spontaneously postpartum; those that persist are managed with the full protocol once breastfeeding has ended.

How is treatment response measured objectively?

Objective response tracking is what separates disciplined dermatology from trial-and-error. At DermaVue Thiruvananthapuram, MD DVL dermatologists record a baseline MASI (Melasma Area and Severity Index) score at the first visit, combining pigment darkness, area and homogeneity across four facial regions. MASI is repeated at each review visit. Patients can see whether a protocol is producing meaningful change rather than relying on memory or mirror comparisons, and the number guides protocol adjustments at 8-, 12- and 24-week decision points.

How long does melasma treatment take and what results are realistic?

Most patients see measurable MASI reduction by weeks 8–12 on combined topical and oral therapy. Visible clinical improvement — the kind patients and family members notice — typically consolidates between months 4 and 6, when laser toning, if indicated, has also been layered in. Epidermal melasma generally clears more completely than dermal or mixed melasma. Realistic long-term expectations are good control with intermittent maintenance, not permanent cure. Any clinic quoting a fixed number of sessions to “remove” melasma is misrepresenting a chronic disease.

Does melasma come back after treatment, and how is relapse managed?

Yes — follow-up studies across populations report relapse rates of 50–80% when maintenance therapy and daily photoprotection are discontinued. At DermaVue relapse is treated as expected, not as failure. The maintenance phase rotates non-hydroquinone topicals (azelaic acid, cysteamine, thiamidol, topical tranexamic acid) every 6–12 months to prevent tolerance, reinforces daily tinted SPF 50+, and schedules dermatologist review every three to four months. When early relapse is detected on MASI scoring, the induction phase is briefly reintroduced rather than waiting for full recurrence.

Why did my pigmentation get worse after using a pharmacy fairness cream?

Many over-the-counter triple-combination creams sold in Indian pharmacies contain potent topical steroids (clobetasol, betamethasone) alongside hydroquinone. The initial lightening is driven by steroid-induced vasoconstriction and melanocyte suppression. Prolonged, unsupervised use causes steroid-dependent skin, telangiectasia, rebound hyperpigmentation on withdrawal and, in some cases, exogenous ochronosis — a permanent blue-grey discolouration that is far harder to treat than the original melasma. DermaVue dermatologists first stabilise this steroid-damaged skin before re-introducing a supervised, appropriate protocol.

Can men get melasma?

Yes. Male patients account for roughly 10–25% of melasma presentations in published Indian dermatology cohorts. Male melasma is less hormonally driven and more commonly associated with cumulative UV exposure and genetic predisposition. The diagnostic workup (Wood lamp, MASI) and therapeutic principles (topical therapy, oral tranexamic acid where indicated, photoprotection, selective laser toning) are identical to those used in female patients, with protocols adjusted for the specific trigger profile.

How much does melasma treatment cost at DermaVue Thiruvananthapuram?

The initial dermatologist consultation at DermaVue Thiruvananthapuram is ₹300 and includes history, Wood lamp examination, Fitzpatrick typing and a baseline MASI score with a written protocol. Ongoing treatment cost depends on severity, subtype and the modalities required — topical-only protocols are the most affordable, oral tranexamic acid adds a modest monthly cost, and laser toning sessions are quoted per session. EMI and package options are available for multi-session protocols and are discussed transparently at the first visit after assessment.

How early before a wedding should I start melasma treatment?

A minimum of five to six months is the evidence-aligned answer. The first 8–12 weeks are needed for topical induction and oral tranexamic acid to show measurable MASI reduction. If laser toning is indicated, an additional 8–12 weeks allows for 4–6 sessions at appropriate intervals, plus a buffer for protocol adjustments and a settled maintenance phase in the final month so the skin is calm on the wedding date. Last-minute aggressive treatment is specifically discouraged because it risks post-inflammatory hyperpigmentation at the worst possible time.

Is melasma hereditary in South Indian families?

Family history is one of the strongest predictors of melasma in published Indian cohorts, and Fitzpatrick IV–V skin has intrinsically higher baseline melanocyte activity. Patients with affected mothers, sisters or aunts benefit from a prevention-oriented consultation before melasma is fully established — this typically includes rigorous tinted iron-oxide photoprotection, maintenance antioxidants and early trigger avoidance counselling, rather than waiting until visible patches demand active therapy.

DermaVue is a physician-owned dermatology network operating seven clinics across Kerala and Tamil Nadu, with its Thiruvananthapuram (Trivandrum) clinic at Poojapura providing specialist melasma assessment and treatment for patients across Thiruvananthapuram district, Kollam, Neyyattinkara, Attingal, Varkala and the Nagercoil border region. Treatment is delivered exclusively by IADVL-registered MD DVL dermatologists, including Dr. Sarath Chandran (MD DVL, Managing Director) and Dr. Minu Liz Mathew (MD DVL), with 1309+ verified Google reviews and a 4.7-star aggregate rating across the network.

The clinic’s melasma protocol follows IADVL and international consensus guidance rather than a single proprietary formula. Every patient begins with Wood lamp classification (epidermal, dermal or mixed), Fitzpatrick phototyping and a baseline MASI (Melasma Area and Severity Index) score, which is repeated at each review visit to track response objectively. Therapy is then staged: modified Kligman-based topical induction, oral tranexamic acid 250 mg twice daily after thromboembolic and hormonal-contraceptive screening, low-fluence Q-switched Nd:YAG 1064 nm laser toning as an adjunct for mixed and recalcitrant cases, and a structured maintenance phase using non-hydroquinone agents such as azelaic acid, cysteamine and thiamidol.

Because melasma is a chronic, relapsing disorder, DermaVue treats photoprotection as equal in weight to the medical therapy itself. Patients are prescribed broad-spectrum SPF 50+ with iron oxides to block the visible-light wavelengths implicated in darker-skin melasma, with reapplication every 3–4 hours and quarterly dermatologist review to catch early relapse on MASI scoring. High-fluence and ablative lasers are actively avoided in Fitzpatrick IV–V melasma because of the documented risk of post-inflammatory hyperpigmentation, and no clinician in the network offers permanent-cure guarantees — a position consistent with published evidence and IADVL consensus.

Achieve Clearer, Even-Toned Skin

Melasma in Thiruvananthapuram demands a structured protocol, not a quick fix. Our board-certified dermatologists treat both men and women with evidence-based approaches calibrated for Kerala's extreme UV. Join 1309+ patients who trust DermaVue.

WhatsApp DermaVue Thiruvananthapuram Call +91 8330860007

Call WhatsApp